Company profile

Novacyt develops, produces, and sells in vitro and molecular diagnostic products for the microbiology, haematology and serology markets. Net sales (not including sold divisions) break down by activity as follows:
  • development of solutions and diagnostic services (51.8%). The group is also developing a manufacturing activity for reagents and kits for bacterial and blood tests;
  • manufacture and sale of molecular screening kits (48.2%; Primerdesign): for laboratories.
The geographical breakdown of sales is as follows: Europe (42%), Asia-Pacific (19.5%), America (20.4%), Middle East (10.5%) and Africa (7.6%). In December 2019, the group sold its cytology solution activity (NOVAprep®).

Source: Cofisem - Last Update: 03 Jul 2020
Key Executives
Chief Executive Officer Graham Mullis
Chief Financial Officer Anthony Dyer
Human Resources Director Wendy Karban
Source: Cofisem - Last Update: 07 Jun 2019
Key figures
Millenium 2018 2017 2016 2015 2014
Net sales 13,721 14,954 11,076 8,892 4,530
Consumed purchases 4,758 3,520 0
Payroll 4,318 3,603 4,248 3,086 2,274
Operating profit -1,385 -4,071 -4,463 -13,185 -1,896
Income tax 32 -2 2 1 0
Net income -4,738 -5,442 -5,711 -13,908 -3,702
Net consolidated income (Group share) -4,738 -5,442 -5,711 -13,908 -3,702
Fiscal year end 12.18 12.17 12.16 12.15 12.14
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 03 Jul 2020
Shareholder information
ABN Amro Bank 17.70 %
Legal and General Group 6.70 %
Talence Selection 3.90 %
Source: Cofisem - Last Update: 07 Jun 2019

Financial analysis

Equity research report, in partnership with Morningstar

View Report

Address

Novacyt

13 Avenue Morane Saulnier
FR-78140 Vélizy-Villacoublay
France
Source: Cofisem - Last Update: 03 Jul 2020

Contact

Graham Mullis
Phone number: + 44 (0)7901 5141 21
Source: Novacyt - Last Update: 03 Jul 2020